Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

Autor: S Trebeschi, SG Drago, NJ Birkbak, I Kurilova, AM Cǎlin, A Delli Pizzi, F Lalezari, DMJ Lambregts, MW Rohaan, C Parmar, EA Rozeman, KJ Hartemink, C Swanton, JBAG Haanen, CU Blank, EF Smit, RGH Beets-Tan, HJWL Aerts

INTRODUCTION: Immunotherapy is regarded one of the major breakthroughs in cancer treatment. Despite its success, only a subset of patients responds - urging the quest for predictive biomarkers. We hypothesize that Artificial Intelligence (AI) algorit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::edace40fc60729c94d50df10fede3ad0

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

Autor: S Trebeschi, SG Drago, NJ Birkbak, I Kurilova, AM Cǎlin, A Delli Pizzi, F Lalezari, DMJ Lambregts, MW Rohaan, C Parmar, EA Rozeman, KJ Hartemink, C Swanton, JBAG Haanen, CU Blank, EF Smit, RGH Beets-Tan, HJWL Aerts

INTRODUCTION: Immunotherapy is regarded one of the major breakthroughs in cancer treatment. Despite its success, only a subset of patients responds - urging the quest for predictive biomarkers. We hypothesize that Artificial Intelligence (AI) algorit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7ae4798e89941679838bda47505c175e

Improving diagnostic accuracy of identifying gastric cancer patients with peritoneal metastases: tumor-guided cell-free DNA analysis of peritoneal fluid.

Autor: van der Sluis K; The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Surgical Oncology, Amsterdam, The Netherlands., van Sandick JW; The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Surgical Oncology, Amsterdam, The Netherlands., Vollebergh MA; The Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Gastrointestinal Oncology, Amsterdam, The Netherlands., van Dieren JM; The Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Gastrointestinal Oncology, Amsterdam, The Netherlands., Hugen N; The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Surgical Oncology, Amsterdam, The Netherlands., Hartemink KJ; The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Surgical Oncology, Amsterdam, The Netherlands., Veenhof AAFA; The Netherlands Cancer Institute - Antoni van Leeuwenhoek, Department of Surgical Oncology, Amsterdam, The Netherlands., Verhoeven E; The Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Pathology, Amsterdam, The Netherlands., van den Berg JG; The Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Pathology, Amsterdam, The Netherlands., Snaebjornsson P; The Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Pathology, Amsterdam, The Netherlands.; Faculty of Medicine, University of Iceland, Reykjavik, Iceland., Noe M; The Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Pathology, Amsterdam, The Netherlands., van Wezel T; The Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Pathology, Amsterdam, The Netherlands., Boelens MC; The Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Pathology, Amsterdam, The Netherlands., Kodach LL; The Netherlands Cancer Institute- Antoni van Leeuwenhoek, Department of Pathology, Amsterdam, The Netherlands. l.kodach@nki.nl.

Publikováno v: Oncogene [Oncogene] 2024 Jun; Vol. 43 (24), pp. 1877-1882. Date of Electronic Publication: 2024 Apr 23.

Author Correction: Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial.

Autor: Verschoor YL; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., van de Haar J; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., van den Berg JG; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., van Sandick JW; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Kodach LL; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., van Dieren JM; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Balduzzi S; Biometrics department, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Grootscholten C; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., IJsselsteijn ME; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands., Veenhof AAFA; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Hartemink KJ; Department of Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Vollebergh MA; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Jurdi A; Natera, Inc, Austin, TX, USA., Sharma S; Natera, Inc, Austin, TX, USA., Spickard E; Natera, Inc, Austin, TX, USA., Owers EC; Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., Bartels-Rutten A; Department of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., den Hartog P; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands., de Miranda NFCC; Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands., van Leerdam ME; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands., Haanen JBAG; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.; Oncology Service, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland., Schumacher TN; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, the Netherlands., Voest EE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Department of Molecular Oncology and Immunology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands.; Oncode Institute, Amsterdam, the Netherlands., Chalabi M; Department of Gastrointestinal Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. m.chalabi@nki.nl.; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, the Netherlands. m.chalabi@nki.nl.

Publikováno v: Nature medicine [Nat Med] 2024 May; Vol. 30 (5), pp. 1499.

Druggable growth dependencies and tumor evolution analysis in patient-derived organoids of neuroendocrine neoplasms from multiple body sites.

Autor: Dayton TL; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands; Oncode Institute, Hubrecht Institute, 3584 CT Utrecht, the Netherlands. Electronic address: talya.dayton@embl.es., Alcala N; Rare Cancers Genomics Team (RCG), Genomic Epidemiology Branch (GEM), International Agency for Research on Cancer/World Health Organisation (IARC/WHO), 69007 Lyon, France., Moonen L; Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, 6229 ER Maastricht, the Netherlands., den Hartigh L; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands., Geurts V; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands., Mangiante L; Rare Cancers Genomics Team (RCG), Genomic Epidemiology Branch (GEM), International Agency for Research on Cancer/World Health Organisation (IARC/WHO), 69007 Lyon, France., Lap L; Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, 6229 ER Maastricht, the Netherlands., Dost AFM; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands; Oncode Institute, Hubrecht Institute, 3584 CT Utrecht, the Netherlands., Beumer J; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands; Oncode Institute, Hubrecht Institute, 3584 CT Utrecht, the Netherlands., Levy S; Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands., van Leeuwaarde RS; Department of Endocrine Oncology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands., Hackeng WM; Department of Pathology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, the Netherlands., Samsom K; Department of Pathology, Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Voegele C; Rare Cancers Genomics Team (RCG), Genomic Epidemiology Branch (GEM), International Agency for Research on Cancer/World Health Organisation (IARC/WHO), 69007 Lyon, France., Sexton-Oates A; Rare Cancers Genomics Team (RCG), Genomic Epidemiology Branch (GEM), International Agency for Research on Cancer/World Health Organisation (IARC/WHO), 69007 Lyon, France., Begthel H; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands., Korving J; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands., Hillen L; Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, 6229 ER Maastricht, the Netherlands., Brosens LAA; Department of Pathology, University Medical Center Utrecht, Utrecht University, 3584 CX Utrecht, the Netherlands., Lantuejoul S; Department of Biopathology, Pathology Research Platform- Synergie Lyon Cancer- CRCL, Centre Léon Bérard Unicancer, 69008 Lyon, France; Université Grenoble Alpes, Grenoble, France., Jaksani S; Hubrecht Organoid Technology, Utrecht 3584 CM, the Netherlands., Kok NFM; Department of Surgery, Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Hartemink KJ; Department of Surgery, Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Klomp HM; Department of Surgery, Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Borel Rinkes IHM; Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht 3508 GA, the Netherlands., Dingemans AM; Department of Pulmonary Diseases, GROW School for Oncology and and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands; Department of Pulmonary Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam 3015 GD, the Netherlands., Valk GD; Department of Endocrine Oncology, University Medical Center Utrecht, 3584 CX Utrecht, the Netherlands., Vriens MR; Department of Endocrine Surgical Oncology, University Medical Center Utrecht, Utrecht 3508 GA, the Netherlands., Buikhuisen W; Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., van den Berg J; Department of Pathology, Netherlands Cancer Institute, Amsterdam 1066 CX, the Netherlands., Tesselaar M; Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, the Netherlands., Derks J; Department of Pulmonary Diseases, GROW School for Oncology and and Reproduction, Maastricht University Medical Centre, Maastricht, the Netherlands., Speel EJ; Department of Pathology, GROW School for Oncology and Reproduction, Maastricht University Medical Centre, 6229 ER Maastricht, the Netherlands., Foll M; Rare Cancers Genomics Team (RCG), Genomic Epidemiology Branch (GEM), International Agency for Research on Cancer/World Health Organisation (IARC/WHO), 69007 Lyon, France., Fernández-Cuesta L; Rare Cancers Genomics Team (RCG), Genomic Epidemiology Branch (GEM), International Agency for Research on Cancer/World Health Organisation (IARC/WHO), 69007 Lyon, France. Electronic address: fernandezcuestal@iarc.who.int., Clevers H; Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences (KNAW) and UMC Utrecht, 3584 CT Utrecht, the Netherlands; Oncode Institute, Hubrecht Institute, 3584 CT Utrecht, the Netherlands. Electronic address: h.clevers@hubrecht.eu.

Publikováno v: Cancer cell [Cancer Cell] 2023 Dec 11; Vol. 41 (12), pp. 2083-2099.e9.